Table 1.
Main characteristics of the study cohort
| Factor | Study cohort (n=63) |
|---|---|
| Sex | |
| Male/Female | 37 (59)/26 (41) |
| Age at diagnosis (yr) | |
| Median (range) | 4.7 (1.8-13.6) |
| Initial WBC count (/mm3) | |
| Median (range) | 11,300 (1,000-269,380) |
| ≤ 50,000/> 50,000 and ≤ 100,000/> 100,000 | 53 (84)/7 (11)/3 (5) |
| Initial CNS involvement | |
| Yes/No | 0 (0)/63 (100) |
| NCI risk group | |
| Standard/High | 48 (76)/15 (24) |
| Prephase steroid responsea) | |
| Good/Poor | 61 (97)/2 (3) |
| MRD at end of induction (TP1) | |
| Yes/No | 6 (10)/56 (90) |
| MRD at end of consolidation (TP2) | |
| Yes/No | 2 (3)/60 (97) |
| Overall risk group | |
| Low/Standard | 39 (62)/3 (5) |
| High/Very high | 15 (24)/6 (10) |
Values are presented as number (%) unless otherwise indicated. WBC, white blood cell; CNS, central nervous system; NCI, National Cancer Institute; MRD, minimal residual disease; TP1, time point 1; TP2, time point 2.
a)
Good steroid response was defined as a peripheral blast count of < 1,000/mm3 after 1 week of prephase steroid treatment.